Tecentriq wins FDA priority review for certain early NSCLC patients

3rd August 2021 Uncategorised 0

Tecentriq is first and only cancer immunotherapy with positive Phase III results in adjuvant lung cancer setting

More: Tecentriq wins FDA priority review for certain early NSCLC patients
Source: News